Related Experiment Video
Updated: Sep 22, 2025
11:35
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
58.2K
[Disability Progression in SPMS Despite Therapeutic Intervention: Refractory SPMS].
1Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|May 19, 2022
Summary
New disease-modifying drugs (DMDs) offer hope for progressive multiple sclerosis (MS), but their impact on neurodegeneration remains limited. This review examines current DMD efficacy and strategies for managing treatment-refractory cases.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Progressive multiple sclerosis (MS) presents significant treatment challenges.
- Current disease-modifying drugs (DMDs) primarily target MS inflammation.
- The neurodegenerative component of MS is not fully addressed by existing therapies.
Purpose of the Study:
- To review the efficacy of approved DMDs for secondary progressive MS (SPMS).
- To discuss management strategies for treatment-refractory SPMS.
Main Methods:
- Literature review of approved DMDs for SPMS.
- Analysis of treatment outcomes focusing on inflammatory and neurodegenerative aspects.
- Discussion of clinical management approaches.
Main Results:
- Approved DMDs like ocrelizumab and Siponimod show efficacy in treating progressive MS.
- These therapies mainly impact the inflammatory processes, with modest effects on neurodegeneration.
- Management of treatment-refractory SPMS remains a clinical challenge.
Conclusions:
- While DMDs represent a new era in MS treatment, they do not fully resolve the disease's complexities.
- Further research and novel therapeutic strategies are needed for the neurodegenerative aspects of progressive MS.
- Effective management of treatment-refractory SPMS requires a multifaceted approach.
